SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. (Q38821595)

6 September 2017

title

SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. (English)

1 reference

6 September 2017

1 reference

Elena Nicod

1

1 reference

6 September 2017

Panos Kanavos

series ordinal

2

1 reference

6 September 2017

publication date

14 September 2016

1 reference

International Journal of Technology Assessment in Health Care

6 September 2017

published in

1 reference

6 September 2017

volume

32

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

218-232

1 reference

Evidence, values, and decision making

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

National Institute for Clinical Excellence and its value judgments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Why we need observational studies to evaluate the effectiveness of health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

De Testimonio: on the evidence for decisions about the use of therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

EBM, HTA, and CER: clearing the confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Accountability for reasonableness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Resource allocation, social values and the QALY: a review of the debate and empirical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

How much is the life of a cancer patient worth? A pharmaco-economic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Orphan drugs policies: a suitable case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Accountability for reasonableness: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

Is it time to revisit orphan drug policies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

Welfarism vs. extra-welfarism

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

A note on a discussion group study of public preferences regarding priorities in the allocation of donor kidneys

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

Assessing the economic challenges posed by orphan drugs

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

Health technology assessment: lessons learned from around the world--an overview

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

1 reference

https://api.crossref.org/works/10.1017%2FS0266462316000416

7 January 2021

10.1017/S0266462316000416

Identifiers

DOI

1 reference

release_iofecrehy5eilktr6ld2k4bp5q

6 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iofecrehy5eilktr6ld2k4bp5q

24 November 2022

mapped directly with Wikidata item

1 reference